Utility of capsule endoscopy in the diagnosis of gastrointestinal graft-versus-host disease.

Introduction And Aim: Graft-versus-host disease (GvHD) is a complication of hematopoietic cell transplantation, and the small bowel is one of the main targets in the gastrointestinal tract. Capsule endoscopy is a safe procedure and can be useful in the diagnosis of GvHD. The aim of the present study was to compare the diagnostic yield of capsule endoscopy with the histopathologic findings in GvHD.

Adherence to recommendations for endoscopy practice during COVID-19 pandemic in Latin America: how are we doing it?

Background And Aims: Digestive endoscopy is considered a high-risk procedure for COVID-19. Recommendations have been made for its practice during the pandemic. This study was conducted to determine adherence to recommendations for endoscopy practice during the COVID-19 pandemic in Latin America (LA).

Comparison in the Diagnostic Yield between "Pillcam SB3" Capsule Endoscopy and "OMOM Smart Capsule 2" in Small Bowel Bleeding: A Randomized Head-to-Head Study.

Introduction: Capsule endoscopy (CE) is the first-line tool for diagnosis of small bowel bleeding. There are some studies that have compared different types of CE. OMOM CE is one of the newest in the market and has not been compared with other types of CE.

Feasibility of using an led-probe in third-space endoscopy: a clinical study.

Background: Third-space endoscopy is a novel, safe, and effective method for treating different gastrointestinal conditions. However, several failed endoscopic procedures are attributed to incomplete myotomy. Lighting devices are used to prevent organic injuries.

Clinical feasibility of a new antireflux ablation therapy on gastroesophageal reflux disease (with video).

Backgrounds And Aims: New mucosal resective and ablative endoscopic procedures based on gastric cardiac remodeling to prevent reflux have appeared. We aimed to evaluate the feasibility of a new ablative technique named antireflux ablation therapy (ARAT) for control of GERD in patients without hiatal hernia.

Methods: Patients with proton pump inhibitor (PPI)-refractory GERD without hiatal hernia underwent ARAT between January 2016 and October 2019.